New drug combo aims to make inoperable bile duct cancer removable
NCT ID NCT07433673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy can shrink advanced bile duct tumors enough for surgery. About 20 adults with locally advanced, inoperable bile duct cancer will receive the combination treatment. The main goal is to see how many tumors become surgically removable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Dye-Free laser imaging could replace standard dye in colorectal surgery
- Supercharged t cells take on Hard-to-Treat cancers
- New drug INV-8989 targets Hard-to-Treat cancers with KRAS G12D mutation
- Could a plant-based supplement calm chemo-related diarrhea?
- New cocktail of drugs shows promise for tough bile duct cancer